Elsevier

Vaccine

Volume 34, Issue 20, 29 April 2016, Pages 2299-2304
Vaccine

A prospective cohort study assessing the reactogenicity of pertussis and influenza vaccines administered during pregnancy

https://doi.org/10.1016/j.vaccine.2016.03.084Get rights and content

Highlights

  • Few cohort studies have examined the safety of pertussis and influenza vaccines given during pregnancy.

  • This cohort study prospectively measured adverse events following immunization in 4347 pregnant women.

  • One in 10 women reported a common adverse event following immunization.

  • Women who received pertussis vaccine during pregnancy more commonly reported a local reaction.

  • These results support the safety of maternal pertussis and influenza vaccination.

Abstract

Background

Pertussis vaccination during pregnancy can prevent 91% of infant infections. In 2015, antenatal pertussis vaccination programs were introduced across Australia.

Methods

To monitor the safety of this program, pregnant women who received trivalent influenza vaccine (TIV) and/or diphtheria-tetanus-acellular pertussis vaccine (dTpa) were surveyed by text message seven days post-vaccination about possible adverse events following immunization (AEFI). Univariate logistic regression models were used to calculate the odds of reporting an AEFI following dTpa compared to TIV. Similar analyses were used to compare AEFI reported by women who received a previous dose of dTpa in 2011/2012 as part of a state-wide cocooning program.

Results

Of 5155 women, 4347 (84.3%) replied; 10.8% indicated they experienced an AEFI. There was no difference in the proportion of women who reported any reaction by vaccine; however, women who received dTpa were more likely to report a local reaction than women who received TIV (7.1% and 3.2%, respectively; OR: 2.29; 95% CI: 1.61–3.26). There was evidence suggesting local reactions were more common among women with a previous dose of dTpa (11.4%) compared to women with no previous dose (6.0%; OR: 2.00; 95% CI: 0.95–4.25); 11 (0.3%) women reported attending a hospital emergency department. Subsequent follow-up indicated symptoms resolved and mother and infant were healthy. There was no difference in the proportion of women attending hospital by vaccine (p > 0.05).

Discussion

Data on systemic and local reactions following receipt of TIV and dTpa during pregnancy support the safety of antenatal vaccination.

Introduction

Vaccination during pregnancy is an important public health intervention for preventing serious disease in young infants. Maternal immunization has been shown to prevent 63% of infections with laboratory-confirmed influenza in infants <6 months [1] and 91% of infections with Bordetella pertussis in infants <3 months [2]. In Australia, the Royal Australian and New Zealand College of Obstetricians and Gynaecologists has recommended influenza vaccination during pregnancy since 2011 [3], and programs providing pertussis vaccination to pregnant women were introduced by Australian states and territories in 2015. Recommendations for maternal vaccination are relatively new, and uptake of influenza and pertussis vaccines has historically been poor [4], [5], [6], [7], [8]. The safety of vaccines administered during pregnancy is a commonly cited reason for vaccine refusal in pregnant women [9], [10], [11], demonstrating the importance of routine vaccine safety surveillance in this group.

The safety of influenza vaccines administered during pregnancy has been thoroughly studied, with results supporting the safety of antenatal influenza vaccination [12], [13], [14], [15], [16]. Following the introduction of antenatal pertussis vaccination programs in developed countries, more recent studies have been published which support the safety of pertussis vaccination during pregnancy [17], [18], [19], [20]. While studies support the safety of pertussis vaccination during pregnancy, they have largely been restricted to retrospective cohort studies [17], [18], [19], [20], passive surveillance systems [21], and small randomized clinical trials [22]. To date, a single study has evaluated the safety profile of influenza and pertussis vaccines administered concomitantly [17], and one recently published study has explored the safety of pertussis vaccination in pregnant women with a recent history of prior pertussis vaccination [23]. The goal of the current study was to prospectively measure the reactogenicity of seasonal inactivated trivalent influenza vaccine (TIV) and diphtheria-tetanus-acellular pertussis (dTpa) vaccines administered in a cohort of pregnant women in Western Australia.

Section snippets

Methods

The Western Australia Department of Health (WA Health) has routinely monitored the safety of TIV administered to pregnant women since 2012 [24]. In 2015, an antenatal pertussis vaccination program was introduced for women in the third trimester of pregnancy [25]. Following the introduction of this program, the routine vaccine safety monitoring program was expanded to include dTpa vaccines administered during pregnancy.

Under this program, women were surveyed seven days post-vaccination about

Results

A total of 6402 women were recorded as receiving TIV and/or dTpa during pregnancy (Fig. 1). Of these, 5155 (80.5%) women provided a mobile phone number and consented to follow-up by the WA Department of Health: 1877 (36.4%) received TIV exclusively, 1427 (27.7%) received dTpa exclusively, and 1851 (35.9%) received TIV and dTpa concomitantly. Complete AEFI information was obtained from 1584 (84.4%) women who received TIV exclusively, 1257 (88.1%) who received dTpa exclusively, and 1506 (81.4%)

Adverse events by type of vaccine

Follow-up took place between 13 April 2015 and 08 June 2015 (Fig. 2). A total of 468 (10.8%) women reported an AEFI to the system. There was no difference in the proportion of women who reported an AEFI by vaccine group; 10.3% of women who received TIV exclusively reported experiencing an AEFI within seven days of vaccination. Similarly, 11.4% of women who received dTpa exclusively and 10.7% of women who received TIV and dTpa concomitantly reported experiencing an AEFI (p = 0.39 and p = 0.77,

Adverse events by vaccination history

A record of pertussis vaccination in 2012 was located for 70 (2.5%) of the women who received a dTpa vaccine in 2015 (Table 3). Women who received a dTpa dose in 2011/2012 and 2015 more frequently reported experiencing any AEFI compared to women who had no dose recorded in 2011/2012 (p = 0.04) and had significantly greater odds of visiting a general practitioner for treatment of an AEFI (p = 0.03). There was evidence suggesting women who received a dTpa dose in 2011/2012 and 2015 were at greater

Discussion

To our knowledge, this is the first prospective cohort study summarizing the reactogenicity of TIV and dTpa administered during pregnancy. Prospective follow-up of 4347 pregnant women indicated that one in 10 women who receive TIV, dTpa, or TIV and dTpa concomitantly experience any reaction during the week following vaccination. While there was no difference in the proportion of women who reported any reaction, a significantly higher proportion of women who received dTpa reported experiencing

Acknowledgements

The authors would like to acknowledge Caroline Talbot, Rachel West, Heidi Hutton, and Jennifer Kent at Vaccine Trials group (Telethon Kids Institute, Perth, Western Australia) for their assistance in conducting telephone interviews. The authors are also grateful to the Improvement Foundation (Adelaide, South Australia) for developing the short message service system for performing follow-up.

Authors’ contribution: AR led the data management and analysis and led the writing of the manuscript; LT

References (33)

  • K. Zaman et al.

    Effectiveness of maternal influenza immunization in mothers and infants

    N Engl J Med

    (2008)
  • Royal Australian and New Zealand College of Obstetricians and Gynecologists (RANZCOG). Influenza vaccination during...
  • M. Henninger et al.

    Trends in influenza vaccine coverage in pregnant women, 2008 to 2012

    Perm J

    (2013)
  • H. Ding et al.

    Influenza vaccination coverage among pregnancy women – United States, 2013–14 influenza season

    MMWR Morb Mortal Wkly Rep

    (2014)
  • E.A. McCarthy et al.

    Increasing uptake of influenza vaccine by pregnant women post H1N1 pandemic: a longitudinal study in Melbourne, Australia, 2010–2014

    BMC Pregnancy Childbirth

    (2015)
  • K.E. Wiley et al.

    Uptake of influenza vaccine by pregnant women: a cross-sectional survey

    Med J Aust

    (2013)
  • Cited by (30)

    • Modification of innate immune responses to Bordetella pertussis in babies from pertussis vaccinated pregnancies

      2021, EBioMedicine
      Citation Excerpt :

      This vaccine strategy helps protect infants in the first weeks of life through the transfer of antigen-specific maternal antibodies across the placenta during pregnancy. Both maternal Tdap-IPV [8,10–12] and Tdap vaccination [13–16], have been demonstrated to be both safe and effective in pregnancy. Several studies [17–20], but not all [21], have demonstrated that maternal Tdap-IPV immunisation during pregnancy blunts the offspring's antibody responses to primary pertussis immunisation.

    • Active SMS-based surveillance of adverse events following immunisation with influenza and pertussis-containing vaccines in Australian pregnant women using AusVaxSafety

      2020, Vaccine
      Citation Excerpt :

      Although they are becoming more common, the few clinical trials of vaccination in pregnancy have recruited small numbers of women [25–29]. Only a few studies have prospectively monitored the safety of maternal vaccination [30,31], concomitant IIV and dTpa administration [21,30–32], repeat dTpa administration in sequential pregnancies [30], or IIV administered in the first trimester [32,33], usually in a limited number of women. AusVaxSafety, a novel, active vaccine safety surveillance system that operates at sentinel immunisation provider sites across Australia, collects brand-specific vaccine safety data through automated SmartVax software, which sends SMS messages containing standardised survey questions to solicit information about adverse events following immunisation (AEFI) directly from vaccine recipients or their caregivers following all routine vaccination encounters.

    View all citing articles on Scopus
    View full text